Advertisement

Special problems in the management of elderly patients with multiple myeloma

  • Author Footnotes
    1 The two authors equally contributed to the manuscript.
    Francesca Gay
    Correspondence
    Corresponding author at: Division of Hematology, University of Turin, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Via Genova 3, 10126 Turin, Italy.
    Footnotes
    1 The two authors equally contributed to the manuscript.
    Affiliations
    Division of Hematology, University of Turin, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin, Italy
    Search for articles by this author
  • Author Footnotes
    1 The two authors equally contributed to the manuscript.
    Alessandra Larocca
    Footnotes
    1 The two authors equally contributed to the manuscript.
    Affiliations
    Division of Hematology, University of Turin, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin, Italy
    Search for articles by this author
  • Author Footnotes
    1 The two authors equally contributed to the manuscript.

      Highlights

      • Elderly myeloma patients are highly heterogeneous and need tailored therapy
      • The frailty score is a valid tool to appropriately evaluate the frailty status
      • Future trials will assess novel agent-based tailored approaches in this setting

      Abstract

      Multiple myeloma (MM) is a neoplastic disease typical of the elderly. Many steps forward have been made in the characterization of patients, and new treatment strategies are available today. Clinical trials represent a major point in the definition of standard treatment, although they usually include fit patients, while frail patients are commonly excluded. Therefore, frail patients may receive treatments that may be too toxic, thus jeopardizing the beneficial effects of therapy. A careful patient assessment is crucial to better characterize patients and consequently to appropriately select treatment. Future trials testing novel agent-based therapies in different subsets of patients will shed light on this important issue and will allow patients to receive appropriate, tailored treatments.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Palumbo A.
        • Anderson K.
        Multiple myeloma.
        N Engl J Med. 2011; 364: 1046-1060https://doi.org/10.1056/NEJMra1011442
        • Kyle R.A.
        • Rajkumar S.V.
        Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma.
        Leukemia. 2009; 23: 3-9https://doi.org/10.1038/leu.2008.291
        • Rajkumar S.V.
        • Dimopoulos M.A.
        • Palumbo A.
        • Blade J.
        • Merlini G.
        • Mateos M.-V.
        • et al.
        International myeloma working group updated criteria for the diagnosis of multiple myeloma.
        Lancet Oncol. 2014; 15: e538-e548https://doi.org/10.1016/S1470-2045(14)70442-5
      1. Cancer statistics for the UK n.d.

        • van de Donk N.W.
        • Lokhorst H.M.
        New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.
        Expert Opin Pharmacother. 2013; 14: 1569-1573https://doi.org/10.1517/14656566.2013.805746
        • Kumar S.K.
        • Dispenzieri A.
        • Lacy M.Q.
        • Gertz M.A.
        • Buadi F.K.
        • Pandey S.
        • et al.
        Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.
        Leukemia. 2014; 28: 1122-1128https://doi.org/10.1038/leu.2013.313
        • Larocca A.
        • Bringhen S.
        • Petrucci M.T.
        • Offidani M.
        • Benevolo G.
        • Galli M.
        • et al.
        Early mortality in elderly patients with newly diagnosed multiple myeloma treated with novel agents.
        Clin Lymphoma Myeloma Leuk. 2015; 15: e42-e43https://doi.org/10.1016/j.clml.2015.07.174
        • Vestal R.E.
        Aging and pharmacology.
        Cancer. 1997; 80: 1302-1310
        • Baker S.D.
        • Grochow L.B.
        Pharmacology of cancer chemotherapy in the older person.
        Clin Geriatr Med. 1997; 13: 169-183
        • Yuen G.J.
        Altered pharmacokinetics in the elderly.
        Clin Geriatr Med. 1990; 6: 257-267
        • Sotaniemi E.A.
        • Arranto A.J.
        • Pelkonen O.
        • Pasanen M.
        Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions.
        Clin Pharmacol Ther. 1997; 61: 331-339https://doi.org/10.1016/S0009-9236(97)90166-1
        • Hulin C.
        • Rodon P.
        • Campion L.
        • Roussel M.
        • Leleu X.
        • Marit G.
        • et al.
        Clinical characteristics, chromosomal abnormalities and outcomes in very elderly patients with multiple myeloma: the IFM experience.
        Blood. 2015; 120 (Abstr): 204
        • Extermann M.
        • Aapro M.
        • Bernabei R.
        • Cohen H.J.
        • Droz J.-P.
        • Lichtman S.
        • et al.
        Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG).
        Crit Rev Oncol Hematol. 2005; 55: 241-252https://doi.org/10.1016/j.critrevonc.2005.06.003
        • Palumbo A.
        • Bringhen S.
        • Mateos M.-V.
        • Larocca A.
        • Facon T.
        • Kumar S.K.
        • et al.
        Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an international myeloma working group report.
        Blood. 2015; 125: 2068-2074https://doi.org/10.1182/blood-2014-12-615187
        • Engelhardt M.
        • Dold S.M.
        • Ihorst G.
        • Zober A.
        • Möller M.
        • Reinhardt H.
        • et al.
        Geriatric assessment in multiple myeloma patients: validation of the international myeloma working group (IMWG) score and comparison with other common comorbidity scores.
        Haematologica. 2016; 101: 1110-1119https://doi.org/10.3324/haematol.2016.148189
        • Engelhardt M.
        • Domm A.-S.
        • Dold S.M.
        • Ihorst G.
        • Reinhardt H.
        • Zober A.
        • et al.
        A concise revised myeloma comorbidity index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients.
        Haematologica. 2017; https://doi.org/10.3324/haematol.2016.162693
        • Takeoka Y.
        • Sakatoku K.
        • Miura A.
        • Yamamura R.
        • Araki T.
        • Seura H.
        • et al.
        Prognostic effect of low subcutaneous adipose tissue on survival outcome in patients with multiple myeloma.
        Clin Lymphoma Myeloma Leuk. 2016; 16: 434-441https://doi.org/10.1016/j.clml.2016.04.010
        • Milani P.
        • Vincent Rajkumar S.
        • Merlini G.
        • Kumar S.
        • Gertz M.A.
        • Palladini G.
        • et al.
        N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma.
        Am J Hematol. 2016; 91: 1129-1134https://doi.org/10.1002/ajh.24532
        • Bringhen S.
        • Mateos M.V.
        • Zweegman S.
        • Larocca A.
        • Falcone A.P.
        • Oriol A.
        • et al.
        Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.
        Haematologica. 2013; 98: 980-987https://doi.org/10.3324/haematol.2012.075051
        • Fried L.P.
        • Guralnik J.M.
        Disability in older adults: evidence regarding significance, etiology, and risk.
        J Am Geriatr Soc. 1997; 45: 92-100
      2. Disability in America. National Academies Press, Washington, D.C.1991https://doi.org/10.17226/1579
        • Adams P.F.
        • Hendershot G.E.
        • Marano M.A.
        Centers for Disease Control and Prevention/National Center for Health Statistics. Current estimates from the National Health Interview Survey.
        Vital Health Stat. 1996; 10: 1999:1-203
        • San Miguel J.F.
        • Schlag R.
        • Khuageva N.K.
        • Dimopoulos M.A.
        • Shpilberg O.
        • Kropff M.
        • et al.
        Bortezomib plus Melphalan and prednisone for initial treatment of multiple myeloma.
        N Engl J Med. 2008; 359: 906-917https://doi.org/10.1056/NEJMoa0801479
        • Mateos M.-V.
        • Richardson P.G.
        • Schlag R.
        • Khuageva N.K.
        • Dimopoulos M.A.
        • Shpilberg O.
        • et al.
        Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
        J Clin Oncol. 2010; 28: 2259-2266https://doi.org/10.1200/JCO.2009.26.0638
        • Bringhen S.
        • Larocca A.
        • Rossi D.
        • Cavalli M.
        • Genuardi M.
        • Ria R.
        • et al.
        Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.
        Blood. 2010; 116: 4745-4753https://doi.org/10.1182/blood-2010-07-294983
        • Moreau P.
        • Pylypenko H.
        • Grosicki S.
        • Karamanesht I.
        • Leleu X.
        • Grishunina M.
        • et al.
        Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.
        Lancet Oncol. 2011; 12: 431-440https://doi.org/10.1016/S1470-2045(11)70081-X
        • Palumbo A.
        • Bringhen S.
        • Rossi D.
        • Cavalli M.
        • Larocca A.
        • Ria R.
        • et al.
        Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.
        J Clin Oncol. 2010; 28: 5101-5109https://doi.org/10.1200/JCO.2010.29.8216
        • Palumbo A.
        • Bringhen S.
        • Larocca A.
        • Rossi D.
        • Di Raimondo F.
        • Magarotto V.
        • et al.
        Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
        J Clin Oncol. 2014; 32: 634-640https://doi.org/10.1200/JCO.2013.52.0023
        • Mateos M.-V.
        • Oriol A.
        • Martínez-López J.
        • Gutiérrez N.
        • Teruel A.-I.
        • de Paz R.
        • et al.
        Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myelom.
        Lancet Oncol. 2010; 11: 934-941https://doi.org/10.1016/S1470-2045(10)70187-X
        • Mateos M.-V.
        • Oriol A.
        • Martinez-Lopez J.
        • Teruel A.-I.
        • Lopez de la Guia A.
        • Lopez J.
        • et al.
        GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?.
        Blood. 2014; 124: 1887-1893https://doi.org/10.1182/blood-2014-05-573733
        • Facon T.
        • Lee J.H.
        • Moreau P.
        • Niesvizky R.
        • Dimopoulos M.A.
        • Hajek R.
        • et al.
        Phase 3 study (CLARION) of carfilzomib, Melphalan, prednisone (KMP) v Bortezomib, Melphalan, prednisone (VMP) in newly diagnosed multiple myeloma (NDMM).
        Int Myeloma Work. 2017; (p. abstract OP-044): e37-e38
        • Benboubker L.
        • Dimopoulos M.A.
        • Dispenzieri A.
        • Catalano J.
        • Belch A.R.
        • Cavo M.
        • et al.
        Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
        N Engl J Med. 2014; 371: 906-917https://doi.org/10.1056/NEJMoa1402551
        • Delforge M.
        • Minuk L.
        • Eisenmann J.-C.
        • Arnulf B.
        • Canepa L.
        • Fragasso A.
        • et al.
        Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.
        Haematologica. 2015; 100: 826-833https://doi.org/10.3324/haematol.2014.120121
        • Mateos M.-V.
        • Martínez-López J.
        • Hernández M.-T.
        • Ocio E.-M.
        • Rosiñol L.
        • Martínez R.
        • et al.
        Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM.
        Blood. 2016; 127: 420-425https://doi.org/10.1182/blood-2015-08-666537
        • Durie B.G.M.
        • Hoering A.
        • Abidi M.H.
        • Rajkumar S.V.
        • Epstein J.
        • Kahanic S.P.
        • et al.
        Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
        Lancet (London, England). 2017; 389: 519-527https://doi.org/10.1016/S0140-6736(16)31594-X
        • Laubach J.
        • Garderet L.
        • Mahindra A.
        • Gahrton G.
        • Caers J.
        • Sezer O.
        • et al.
        Management of relapsed multiple myeloma: recommendations of the international myeloma working group.
        Leukemia. 2016; 30: 1005-1017https://doi.org/10.1038/leu.2015.356
        • Laubach J.P.
        • Voorhees P.M.
        • Hassoun H.
        • Jakubowiak A.
        • Lonial S.
        • Richardson P.G.
        Current strategies for treatment of relapsed/refractory multiple myeloma.
        Expert Rev Hematol. 2014; 7: 97-111https://doi.org/10.1586/17474086.2014.882764
        • Dimopoulos M.A.
        • Moreau P.
        • Palumbo A.
        • Joshua D.
        • Pour L.
        • Hájek R.
        • et al.
        Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
        Lancet Oncol. 2016; 17: 27-38https://doi.org/10.1016/S1470-2045(15)00464-7
        • Dimopoulos M.
        • Spencer A.
        • Attal M.
        • Prince H.M.
        • Harousseau J.-L.
        • Dmoszynska A.
        • et al.
        Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
        N Engl J Med. 2007; 357: 2123-2132https://doi.org/10.1056/NEJMoa070594
        • Weber D.M.
        • Chen C.
        • Niesvizky R.
        • Wang M.
        • Belch A.
        • Stadtmauer E.A.
        • et al.
        Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
        N Engl J Med. 2007; 357: 2133-2142https://doi.org/10.1056/NEJMoa070596
        • Larocca A.
        • Palumbo A.
        How I treat fragile myeloma patients.
        Blood. 2015; 126: 2179-2185https://doi.org/10.1182/blood-2015-05-612960
        • Palumbo A.
        • Mina R.
        Management of older adults with multiple myeloma.
        Blood Rev. 2013; 27: 133-142https://doi.org/10.1016/j.blre.2013.04.001
        • Gay F.
        • Palumbo A.
        Multiple myeloma: management of adverse events.
        Med Oncol. 2010; 27: 646-653https://doi.org/10.1007/s12032-009-9262-4
        • Tonelli M.
        • Hemmelgarn B.
        • Reiman T.
        • Manns B.
        • Reaume M.N.
        • Lloyd A.
        • et al.
        Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis.
        Can Med Assoc J. 2009; 180: E62-E71https://doi.org/10.1503/cmaj.090470
        • Neumann S.
        • Krause S.W.
        • Maschmeyer G.
        • Schiel X.
        • von Lilienfeld-Toal M.
        Primary prophylaxis of bacterial infections and pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors.
        Ann Hematol. 2013; 92: 433-442https://doi.org/10.1007/s00277-013-1698-0
        • de Naurois J.
        • Novitzky-Basso I.
        • Gill M.J.
        • Marti F.M.
        • Cullen M.H.
        • Roila F.
        • et al.
        Management of febrile neutropenia: ESMO Clinical Practice Guidelines.
        Ann Oncol Off J Eur Soc Med Oncol. 2010; 21: v252-v256https://doi.org/10.1093/annonc/mdq196
        • Palumbo A.
        • Rajkumar S.V.
        • Dimopoulos M.A.
        • Richardson P.G.
        • San Miguel J.
        • Barlogie B.
        • et al.
        Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
        Leukemia. 2008; 22: 414-423https://doi.org/10.1038/sj.leu.2405062
        • Palumbo A.
        • Palladino C.
        Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance.
        Ther Adv Drug Saf. 2012; 3: 255-266https://doi.org/10.1177/2042098612452291